Allscripts

## Lorenzen Lucas

1073911087

Reporting Period : $\quad(1 / 1 / 2016-12 / 31 / 2016)$

Payer Filter:

## All Payers

| ID | Measure | NQS Domain | Num | Den | IPP | Excl | Excp | Score |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NQF 0002 (V4) | Appropriate Testing for Children with Pharyngitis | Efficient Use of Healthcare Resources | 34 | 122 | 127 | 5 | 0 | 28\% |
| NQF 0004 a (V4) | Initiation and Engagement of Alcohol and Other Drug Dependence Treatment | Clinical Processes/Effectiveness | 0 | 375 | 592 | 217 | 0 | 0\% |
| NQF 0004 a S1 (V4) | Initiation and Engagement of Alcohol and Other Drug Dependence Treatment Patients age 13-17 | Clinical Processes/Effectiveness | 0 | 7 | 11 | 4 | 0 | 0\% |
| NQF 0004 a S2 (V4) | Initiation and Engagement of Alcohol and Other Drug Dependence Treatment Patients age >=18 | Clinical Processes/Effectiveness | 0 | 368 | 581 | 213 | 0 | 0\% |
| NQF 0004 b (V4) | Initiation Engagement of Alcohol and Other Drugs | Clinical Processes/Effectiveness | 0 | 375 | 592 | 217 | 0 | 0\% |
| NQF 0004 b S1 (V4) | Initiation Engagement of Alcohol and Other Drugs Patients age 13-17 | Clinical Processes/Effectiveness | 0 | 7 | 11 | 4 | 0 | 0\% |
| NQF 0004 b S2 (V4) | Initiation Engagement of Alcohol and Other Drugs Patients age >=18 | Clinical Processes/Effectiveness | 0 | 368 | 581 | 213 | 0 | 0\% |
| NQF 0018 (V4) | Controlling High Blood Pressure | Clinical Processes/Effectiveness | 762 | 1,027 | 1,053 | 26 | 0 | 74\% |
| NQF 0022 a (V4) | Use Of High Risk Meds In Elderly | Patient Safety | 196 | 863 | 863 | 0 | 0 | 23\% |
| NQF 0022 b (V4) | Use High Risk Elderly Med Greater than 2 Counts | Patient Safety | 46 | 863 | 863 | 0 | 0 | 5\% |
| NQF 0024 a (V4) | BMI Child 3 to 17 Performed | Population and Public Health | 943 | 946 | 975 | 29 | 0 | 100\% |
| NQF 0024 a S1 (V4) | BMI Child 3 to 17 Performed Patients age 3-10 | Population and Public Health | 415 | 418 | 443 | 25 | 0 | 99\% |
| NQF 0024 a S2 (V4) | BMI Child 3 to 17 Performed Patients age 11-16 | Population and Public Health | 528 | 528 | 532 | 4 | 0 | 100\% |
| NQF 0024 b (V4) | Nutrition Counseling Child 3 to 17 Performed | Population and Public Health | 15 | 946 | 975 | 29 | 0 | 2\% |
| NQF 0024 b S1 (V4) | Nutrition Counseling Child 3 to 17 Performed Patients age 310 | Population and Public Health | 6 | 418 | 443 | 25 | 0 | 1\% |
| NQF 0024 b S2 (V4) | Nutrition Counseling Child 3 to 17 Performed Patients age 1116 | Population and Public Health | 9 | 528 | 532 | 4 | 0 | 2\% |
| NQF 0024 c (V4) | Activity Counseling Child 3 to 17 Performed | Population and Public Health | 5 | 946 | 975 | 29 | 0 | 1\% |
| NQF 0024 c S1 (V4) | Activity Counseling Child 3 to 17 Performed Patients age 3-10 | Population and Public Health | 1 | 418 | 443 | 25 | 0 | 0\% |
| NQF 0024 c S2 (V4) | Activity Counseling Child 3 to 17 Performed Patients age 1116 | Population and Public Health | 4 | 528 | 532 | 4 | 0 | 1\% |
| NQF 0028 (V4) | Preventive Care and Screening Tobacco Use Screening and Cessation Intervention | Population and Public Health | 2,871 | 2,983 | 2,983 | 0 | 0 | 96\% |
| NQF 0032 (V4) | Cervical Cancer Screening | Clinical Processes/Effectiveness | 586 | 1,034 | 1,219 | 185 | 0 | 57\% |
| NQF 0033 (V4) | Chlamydia Screening for Women | Population and Public Health | 11 | 112 | 119 | 7 | 0 | 10\% |
| NQF 0033 S1 (V4) | Chlamydia Screening for Women Patients age 16-19 | Population and Public Health | 10 | 68 | 73 | 5 | 0 | 15\% |
| NQF 0033 S2 (V4) | Chlamydia Screening for Women Patients age 20-23 | Population and Public Health | 1 | 44 | 46 | 2 | 0 | 2\% |
| NQF 0034 (V4) | Colorectal Cancer Screening | Clinical Processes/Effectiveness | 1,130 | 1,422 | 1,440 | 18 | 0 | 79\% |
| NQF 0036 (V4) | Use of Appropriate Medications for Asthma | Clinical Processes/Effectiveness | 21 | 26 | 41 | 15 | 0 | 81\% |
| NQF 0036 S1 (V4) | Use of Appropriate Medications for Asthma Patients age 5-10 | Clinical Processes/Effectiveness | 9 | 11 | 15 | 4 | 0 | 82\% |
| NQF 0036 S2 (V4) | Use of Appropriate Medications for Asthma Patients age 1117 | Clinical Processes/Effectiveness | 8 | 9 | 12 | 3 | 0 | 89\% |
| NQF 0036 S3 (V4) | Use of Appropriate Medications for Asthma Patients age 1849 | Clinical Processes/Effectiveness | 2 | 4 | 6 | 2 | 0 | 50\% |
| NQF 0036 S4 (V4) | Use of Appropriate Medications for Asthma Patients age 5063 | Clinical Processes/Effectiveness | 2 | 2 | 8 | 6 | 0 | 100\% |
| NQF 0038 (V4) | Childhood Immunization Status | Population and Public Health | 15 | 51 | 51 | 0 | 0 | 29\% |
| NQF 0041 (V5) | Preventive Care and Screening Influenza Immunization | Population and Public Health | 275 | 3,240 | 4,541 | 0 | 8 | 8\% |
| NQF 0043 (V4) | Pneumonia Vaccination Status for Older Adults | Clinical Processes/Effectiveness | 492 | 933 | 933 | 0 | 0 | 53\% |
| NQF 0052 (V5) | Use of Imaging Studies for Low Back Pain | Efficient Use of Healthcare Resources | 132 | 136 | 342 | 206 | 0 | 97\% |
| NQF 0055 (V4) | Diabetes Eye Exam | Clinical Processes/Effectiveness | 1 | 849 | 849 | 0 | 0 | 0\% |
| NQF 0056 (V4) | Diabetes Foot Exam | Clinical Processes/Effectiveness | 20 | 842 | 849 | 7 | 0 | 2\% |
| NQF 0059 (V4) | Diabetes Hemoglobin A1c Poor Control | Clinical Processes/Effectiveness | 126 | 849 | 849 | 0 | 0 | 15\% |
| NQF 0060 (V4) | Hemoglobin A1c Test for Pediatric Patients | Clinical Processes/Effectiveness | 4 | 6 | 6 | 0 | 0 | 67\% |
| NQF 0062 (V4) | Diabetes Urine Protein Screening | Clinical Processes/Effectiveness | 818 | 849 | 849 | 0 | 0 | 96\% |
| NQF 0068 (V4) | IVD Use of Aspirin or Another Antithrombotic | Clinical Processes/Effectiveness | 343 | 431 | 431 | 0 | 0 | 80\% |
| NQF 0069 (V4) | Approp Treatment for Children with Upper Resp Infection | Efficient Use of Healthcare Resources | 67 | 70 | 433 | 363 | 0 | 96\% |
| NQF 0070 a (V4) | CAD Beta Blocker Therapy for Moderate to Severe LVSD or LVEF less than 40 percent | Clinical Processes/Effectiveness | 0 | 0 | 263 | 0 | 0 | 0\% |
| NQF 0070 b (V4) | CAD Beta Blocker Therapy for Prior Myocardial Infarction | Clinical Processes/Effectiveness | 0 | 0 | 263 | 0 | 0 | 0\% |
| NQF 0081 (V4) | Heart Failure ACE Inhibitor or ARB Therapy for LVSD | Clinical Processes/Effectiveness | 0 | 0 | 170 | 0 | 0 | 0\% |
| NQF 0083 (V4) | Heart Failure Beta Blocker Therapy for LVSD | Clinical Processes/Effectiveness | 0 | 0 | 170 | 0 | 0 | 0\% |
| NQF 0101 (V4) | Falls Screening for Future Fall Risk | Patient Safety | 262 | 902 | 933 | 0 | 31 | 29\% |
| NQF 0104 (V4) | Adult Major Depressive Disorder Suicide Risk Assessments | Clinical Processes/Effectiveness | 0 | 938 | 938 | 0 | 0 | 0\% |

Allscripts
Lorenzen Lucas
Reporting Period : $\quad(1 / 1 / 2016-12 / 31 / 2016)$

1073911087
Reporting Period : ( $1 / 1 / 2016-12 / 31 / 2016$ )

Payer Filter: All Payers

| ID | Measure | NQS Domain | Num | Den | IPP | Excl | Excp | Score |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NQF 0105 a (V4) | Antidepressant Medication for at Least 84 days | Clinical Processes/Effectiveness | 0 | 16 | 81 | 65 | 0 | 0\% |
| NQF 0105 b (V4) | Antidepressant Medication for at Least 180 days | Clinical Processes/Effectiveness | 0 | 16 | 81 | 65 | 0 | 0\% |
| NQF 0108 a (V5) | ADHD Follow Up Care for Children Prescribed ADHD Meds During 30 Day Initiation Phase | Clinical Processes/Effectiveness | 4 | 21 | 30 | 9 | 0 | 19\% |
| NQF 0108 b (V5) | ADHD Follow Up Care for Children Prescribed ADHD Meds Visit with 2 Plus Followups | Clinical Processes/Effectiveness | 0 | 0 | 0 | 0 | 0 | 0\% |
| NQF 0384 (V4) | Oncologys Medical and Radiation Pain Intensity Quantified | Patient and Family Engagement | 0 | 0 | 0 | 0 | 0 | 0\% |
| NQF 0385 (V5) | Colon Cancer Chemotherapy for AJCC Stage III Colon Cancer Patients | Clinical Processes/Effectiveness | 0 | 0 | 17 | 0 | 0 | 0\% |
| NQF 0387 (V4) | Breast Cancer Hormonal Therapy for Stage IC IIIC Estrogen or Progeteron Receptor | Clinical Processes/Effectiveness | 0 | 0 | 34 | 0 | 0 | 0\% |
| NQF 0389 (V5) | Prostate Cancer Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients | Efficient Use of Healthcare Resources | 0 | 0 | 45 | 0 | 0 | 0\% |
| NQF 0405 a (V4) | HIV AIDS PCP prophylaxis within 3 months of CD4 below 200 | Clinical Processes/Effectiveness | 0 | 0 | 0 | 0 | 0 | 0\% |
| NQF 0405 b (V4) | HIV AIDS PCP prophylaxis within 3 months of CD4 below 500 or 15 percent | Clinical Processes/Effectiveness | 0 | 0 | 0 | 0 | 0 | 0\% |
| NQF 0405 c (V4) | HIV AIDS PCP prophylaxis at time of HIV diagnosis | Clinical Processes/Effectiveness | 0 | 0 | 0 | 0 | 0 | 0\% |
| NQF 0418 (V5) | Preventive Care and Screening for Clinical Depression and Follow Up Plan | Population and Public Health | 0 | 2,889 | 3,918 | 1,029 | 0 | 0\% |
| NQF 0419 (V5) | Documentation of Current Meds in the Medical Record | Patient Safety | 3,903 | 4,044 | 4,044 | 0 | 0 | 97\% |
| NQF 0421 a (V4) | BMI Adult 18 to 64 Performed | Population and Public Health | 1,103 | 2,310 | 2,402 | 92 | 0 | 48\% |
| NQF 0421 b (V4) | BMI Adult 65 or Older Performed | Population and Public Health | 533 | 924 | 933 | 9 | 0 | 58\% |
| NQF 0710 (V4) | Depression Remission at Twelve Months | Clinical Processes/Effectiveness | 0 | 0 | 0 | 0 | 0 | 0\% |
| NQF 0712 a (V4) | Depression Utilization of the PHQ 9 Tool Last 4 months | Clinical Processes/Effectiveness | 0 | 644 | 709 | 65 | 0 | 0\% |
| NQF 0712 b (V4) | Depression Utilization of the PHQ 9 Tool Second 4 Months | Clinical Processes/Effectiveness | 0 | 745 | 811 | 66 | 0 | 0\% |
| NQF 0712 c (V4) | Depression Utilization of the PHQ 9 Tool First 4 Months | Clinical Processes/Effectiveness | 0 | 731 | 799 | 68 | 0 | 0\% |
| NQF 1365 (V4) | Child and Adolescent Major Depressive Disorder Suicide Risk Assessments | Patient Safety | 0 | 63 | 63 | 0 | 0 | 0\% |
| CMS 125 (V4) | Breast Cancer Screening | Clinical Processes/Effectiveness | 684 | 906 | 907 | 1 | 0 | 75\% |
| CMS 149 (V4) | Dementia Cognitive Assessment | Clinical Processes/Effectiveness | 0 | 58 | 60 | 0 | 2 | 0\% |
| CMS 158 (V4) | Pregnant women that had HBsAg testing | Clinical Processes/Effectiveness | 0 | 0 | 0 | 0 | 0 | 0\% |
| CMS 163 (V4) | Diabetes Low Density Lipoprotein Management | Clinical Processes/Effectiveness | 458 | 849 | 849 | 0 | 0 | 54\% |
| CMS 169 (V4) | Bipolar Disorder and Major Depression Appraisal for alcohol or chemical substance use | Clinical Processes/Effectiveness | 0 | 358 | 358 | 0 | 0 | 0\% |
| CMS 182 a (V5) | IVD Complete Lipid Panel and LDL Control | Clinical Processes/Effectiveness | 349 | 431 | 431 | 0 | 0 | 81\% |
| CMS 182 b (V5) | IVD Complete Lipid Panel and LDL Control less than 100 | Clinical Processes/Effectiveness | 277 | 431 | 431 | 0 | 0 | 64\% |
| CMS 22 (V4) | Preventive Care and Screening for High Blood Pressure and Follow Up Documented | Population and Public Health | 1,624 | 3,139 | 3,336 | 178 | 19 | 52\% |
| CMS 50 (V4) | Closing the referral loop receipt of specialist report | Care Coordination | 494 | 2,485 | 2,485 | 0 | 0 | 20\% |
| CMS 56 (V4) | Functional Status Assessment for Hip Replacement | Patient and Family Engagement | 0 | 0 | 0 | 0 | 0 | 0\% |
| CMS 62 (V4) | HIV AIDS Medical Visit | Clinical Processes/Effectiveness | 8 | 10 | 10 | 0 | 0 | 80\% |
| CMS 65 (V5) | Hypertension Improvement in Blood Pressure | Clinical Processes/Effectiveness | 13 | 46 | 46 | 0 | 0 | 28\% |
| CMS 66 (V4) | Functional Status Assessment for Knee Replacement | Patient and Family Engagement | 0 | 0 | 0 | 0 | 0 | 0\% |
| CMS 74 (V5) | Primary Caries Prevention Intervention as Offered by Primary Care Providers including Dentists | Clinical Processes/Effectiveness | 2 | 1,365 | 1,365 | 0 | 0 | 0\% |
| CMS 74 S1 (V5) | Primary Caries Prevention Intervention as Offered by Primary Care Providers including Dentists Patients age 0-4 | Clinical Processes/Effectiveness | 2 | 230 | 230 | 0 | 0 | 1\% |
| CMS 74 S2 (V5) | Primary Caries Prevention Intervention as Offered by Primary Care Providers including Dentists Patients age 5-11 | Clinical Processes/Effectiveness | 0 | 422 | 422 | 0 | 0 | 0\% |
| CMS 74 S3 (V5) | Primary Caries Prevention Intervention as Offered by Primary Care Providers including Dentists Patients age 12-19 | Clinical Processes/Effectiveness | 0 | 713 | 713 | 0 | 0 | 0\% |
| CMS 75 (V4) | Children Who Have Dental Decay or Cavities | Clinical Processes/Effectiveness | 23 | 1,365 | 1,365 | 0 | 0 | 2\% |
| CMS 77 (V4) | HIV AIDS RNA Control for Patients with HIV | Clinical Processes/Effectiveness | 0 | 8 | 8 | 0 | 0 | 0\% |
| CMS 82 (V3) | Maternal Depression Screening | Population and Public Health | 0 | 13 | 13 | 0 | 0 | 0\% |
| CMS 90 (V5) | Functional Status Assessment for Complex Chronic Conditions | Patient and Family Engagement | 0 | 31 | 35 | 4 | 0 | 0\% |

